文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

使用ProtacID对PROTAC特异性和内源性蛋白质相互作用组进行表征。

Characterization of PROTAC specificity and endogenous protein interactomes using ProtacID.

作者信息

Shrestha Suman, Maitland Matthew E R, Jing Laili, Duan Shili, Nie David Y, St-Germain Jonathan, Kanaris Michael, Barsyte-Lovejoy Dalia, Arrowsmith Cheryl H, Raught Brian

机构信息

Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.

Structural Genomics Consortium, University of Toronto, Toronto, ON, Canada.

出版信息

Nat Commun. 2025 Aug 29;16(1):8089. doi: 10.1038/s41467-025-63357-7.


DOI:10.1038/s41467-025-63357-7
PMID:40883309
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12397304/
Abstract

Here we describe ProtacID, a flexible BioID (proximity-dependent biotinylation)-based approach to identify PROTAC-proximal proteins in living cells. ProtacID analysis of VHL- and CRBN-recruiting PROTACs targeting a number of different proteins (localized to chromatin or cellular membranes, and tested across six different human cell lines) demonstrates how this technique can be used to validate PROTAC degradation targets and identify non-productive (i.e. non-degraded) PROTAC-interacting proteins, addressing a critical need in the field of PROTAC development. We also demonstrate that ProtacID can be used to characterize native, endogenous multiprotein complexes without the use of antibodies, or modification of the protein of interest with epitope tags or biotin ligase tagging.

摘要

在此,我们描述了ProtacID,这是一种基于灵活的BioID(邻近依赖性生物素化)方法,用于在活细胞中鉴定PROTAC近端蛋白。对靶向多种不同蛋白质(定位于染色质或细胞膜,并在六种不同人类细胞系中进行测试)的VHL和CRBN招募型PROTAC进行ProtacID分析,证明了该技术可用于验证PROTAC降解靶点并鉴定非生产性(即未降解的)PROTAC相互作用蛋白,满足了PROTAC开发领域的一项关键需求。我们还证明,ProtacID可用于表征天然的内源性多蛋白复合物,而无需使用抗体,也无需用表位标签或生物素连接酶标签对感兴趣的蛋白质进行修饰。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/234b/12397304/244484d54ca6/41467_2025_63357_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/234b/12397304/3d9e5fed8f59/41467_2025_63357_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/234b/12397304/56f7347a0d8f/41467_2025_63357_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/234b/12397304/311b14454f5d/41467_2025_63357_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/234b/12397304/0f2ba8ca45fd/41467_2025_63357_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/234b/12397304/1c62a5901119/41467_2025_63357_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/234b/12397304/244484d54ca6/41467_2025_63357_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/234b/12397304/3d9e5fed8f59/41467_2025_63357_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/234b/12397304/56f7347a0d8f/41467_2025_63357_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/234b/12397304/311b14454f5d/41467_2025_63357_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/234b/12397304/0f2ba8ca45fd/41467_2025_63357_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/234b/12397304/1c62a5901119/41467_2025_63357_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/234b/12397304/244484d54ca6/41467_2025_63357_Fig6_HTML.jpg

相似文献

[1]
Characterization of PROTAC specificity and endogenous protein interactomes using ProtacID.

Nat Commun. 2025-8-29

[2]
In-cell proximity target validation methods for heterobifunctional molecules with CRBN- or VHL-binder using AirID.

Commun Biol. 2025-8-30

[3]
Tumor-targeted PROTAC prodrug nanoplatform enables precise protein degradation and combination cancer therapy.

Acta Pharmacol Sin. 2024-8

[4]
A close-up shot of protein-protein docking, from experiment to theory and reverse with the PROTAC performers.

J Biomol Struct Dyn. 2025-7

[5]
Optimization of the PROTAC linker region of the proteasome substrate receptor hRpn13 rationalized by structural modeling with molecular dynamics.

J Biol Chem. 2025-4-19

[6]
In-Cell Approach to Evaluate E3 Ligases for Use in Targeted Protein Degradation.

J Am Chem Soc. 2025-6-25

[7]
Site-resolved assessment of targeted protein degradation.

Cell Chem Biol. 2025-7-17

[8]
Hijacking the MDM2 E3 Ligase with novel BRD4-Targeting PROTACs in Pancreatic Cancer Cells.

Chembiochem. 2025-5-2

[9]
Development of a versatile system for evaluating the target protein degradation activity of novel ubiquitin ligases utilizing existing PROTACs.

Biochem Biophys Res Commun. 2025-2-16

[10]
Unveiling New Triazoloquinoxaline-Based PROTACs Designed for the Selective Degradation of the ncBAF Chromatin Remodeling Subunit BRD9.

Chemistry. 2025-6-17

本文引用的文献

[1]
Design of a Cereblon construct for crystallographic and biophysical studies of protein degraders.

Nat Commun. 2024-10-15

[2]
PROTAC-DB 3.0: an updated database of PROTACs with extended pharmacokinetic parameters.

Nucleic Acids Res. 2025-1-6

[3]
Recruitment of FBXO22 for targeted degradation of NSD2.

Nat Chem Biol. 2024-12

[4]
A CRISPR activation screen identifies FBXO22 supporting targeted protein degradation.

Nat Chem Biol. 2024-12

[5]
Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer.

Proc Natl Acad Sci U S A. 2024-4-9

[6]
Protein destabilization underlies pathogenic missense mutations in ARID1B.

Nat Struct Mol Biol. 2024-7

[7]
Polycomb repressive complex 2 accessory factors: rheostats for cell fate decision?

Curr Opin Genet Dev. 2024-2

[8]
PROTAC Linkerology Leads to an Optimized Bivalent Chemical Degrader of Polycomb Repressive Complex 2 (PRC2) Components.

ACS Chem Biol. 2023-3-17

[9]
Trans-Proteomic Pipeline: Robust Mass Spectrometry-Based Proteomics Data Analysis Suite.

J Proteome Res. 2023-2-3

[10]
An overview of PROTACs: a promising drug discovery paradigm.

Mol Biomed. 2022-12-20

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索